Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Director/PDMR Shareholding

18 Aug 2022 13:25

RNS Number : 5102W
Belluscura PLC
18 August 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura PLC

("Belluscura" or the "Company" or "Group")

 

Director / PDMR Shareholding

 

LONDON, U.K. AND PLANO, TX, U.S. (18 August 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, confirms that further to the notification on 10 August 2022 in respect of his exercise of options over 690,395 shares, Robert Rauker (CEO) has today transferred 455,064 shares to his ex-wife pursuant to a divorce settlement.

 

Following the transfer, Mr Rauker's holding is 1,191,015 shares and his total interest in the Company is 0.97% of the Company's issued share capital.

 

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP Communications

Anthony Dyer, Chief Financial Officer

 

SPARK Advisory Partners Ltd (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

Dowgate Capital Ltd (Broker & Bookrunner)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

 

MHP Communications (Media & Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Pete Lambie / Matthew Taylor 

or belluscura@mhpc.com

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Robert Rauker

2

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of £0.01 each in Belluscura plc

ISIN : GB00BD3B8Z11

b)

Nature of the transaction

(i) Transfer of shares

c)

Price(s) and volumes(s)

 

Price(s)

Volumes(s)

n/a

455,064

d)

Aggregated information

n/a

e)

Date of the transaction

17 August 2022

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPMTTMTBBBFT
Date   Source Headline
12th Oct 202312:42 pmBUSForm 8.3 - Belluscura plc
12th Oct 20239:55 amRNSForm 8.3 - BELLUSCURA PLC
11th Oct 20234:20 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20235:10 pmRNSForm 8.3 - TMT ACQUISITION PLC
10th Oct 20235:09 pmRNSForm 8.3 - [BELLUSCURA PLC]
10th Oct 20234:40 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20234:21 pmRNSForm 8.3 - BELLUSCURA PLC
10th Oct 20234:19 pmRNSForm 8.3 - TMT Acquisition PLC
10th Oct 20233:54 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:52 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:47 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:42 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:28 pmGNWForm 8.3 - Belluscura PLC
9th Oct 20236:11 pmRNSForm 8.3 - Belluscura Plc
9th Oct 20232:32 pmRNSForm 8.3 - Belluscura PLC
9th Oct 20231:39 pmRNSRule 2.9 Announcement
9th Oct 20238:10 amRNSRule 2.9 Announcement
6th Oct 202312:48 pmRNSConditional Allotment and Issue of Placing
5th Oct 20234:49 pmRNSForm 8.3 - Belluscura PLC
3rd Oct 20236:28 pmRNSReplacement - Placing of Unsecured CLNs
3rd Oct 20231:53 pmRNSDirectorate Change
3rd Oct 20231:38 pmRNSPlacing of Unsecured Convertible Loan Notes
3rd Oct 20231:30 pmRNSStatement regarding possible offer
3rd Oct 20231:30 pmRNSStatement re Possible Offer
26th Sep 20237:00 amRNSBelluscura Receives Approval in Hong Kong
14th Sep 20234:26 pmRNSResult of AGM
13th Sep 20237:00 amRNSHalf-year Report
30th Aug 20237:00 amRNSBelluscura Enters Exclusive License Agreement
16th Aug 20237:00 amRNSOrders for over 6,500 DISCOV-R™ received
1st Aug 20237:00 amRNSBelluscura Signs Distribution Agreement
12th Jul 20237:00 amRNSNotice of AGM and Annual Report 2022
29th Jun 20237:00 amRNSBelluscura Commences Premarket Launch of DISCOV-R™
29th Jun 20237:00 amRNSFinal Results for the year ended 31 December 2022
15th Jun 20237:00 amRNSShare allotment; Director/PDMR Shareholding; Appt.
14th Jun 202312:28 pmRNSResult of General Meeting
1st Jun 20237:00 amRNSResult of Retail Offer
26th May 20237:00 amRNSProposed Board Appointment
25th May 202311:15 amRNSRetail Offer to raise up to £0.5m
25th May 202311:00 amRNSProposed Placing and Subscriptions to raise £3.0m
28th Apr 20237:00 amRNSAdditional Broker Option - Extension
20th Apr 20238:19 amRNSExercise of Warrants and Total Voting Rights
3rd Apr 20237:00 amRNSBelluscura begins manufacturing in China
30th Mar 20237:00 amRNSChange of Auditor
24th Feb 20237:00 amRNSBelluscura POC now marketed through GoodRx®
16th Feb 202311:59 amRNSResult of General Meeting
10th Feb 20237:00 amRNSResult of Broker Option
31st Jan 20233:41 pmRNSPosting of Circular
27th Jan 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.